Eptinezumab
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Eptinezumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Eptinezumab (brand name Vyepti) is an intravenous anti-CGRP monoclonal antibody, marketed in the US and used for migraine prevention. The TxGNN model predicts it may be effective for migraine with brainstem aura, a migraine subtype. There are currently 0 clinical trials and 7 publications for this direction, and none of the publications studies brainstem aura specifically.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine prevention (the approval text is not listed in the source data; this is inferred from the literature) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (BLA761119) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Eptinezumab is an anti-CGRP ligand monoclonal antibody given by intravenous infusion. Detailed mechanism of action data is not available in the source data, but CGRP signaling is central to migraine pathophysiology. Blocking it is the basis for its use in migraine prevention.
Brainstem aura is a migraine subtype, so a CGRP-pathway contribution is plausible. Case reports and small series suggest that anti-CGRP antibodies may help with aura and with monogenic migraine disorders. One post hoc analysis of the PROMISE-1 and PROMISE-2 trials looked at patients with self-reported aura, which is a broader group than brainstem aura.
There are important caveats. Aura mechanisms, such as cortical spreading depression and PACAP-related pathways, may be partly independent of CGRP. A 2025 randomized trial reported that PACAP38-induced migraine attacks are independent of CGRP signaling. The very high TxGNN score most likely reflects the parent migraine indication rather than a distinct mechanism for brainstem aura.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35302389 | 2022 | Post hoc analysis of RCTs | Cephalalgia | Efficacy and safety of eptinezumab for migraine prevention in patients with self-reported aura (PROMISE-1 and PROMISE-2 subgroup) |
| 40229719 | 2025 | RCT (mechanistic, provocation study) | J Headache Pain | PACAP38-induced migraine attacks appear independent of CGRP signaling, which limits how far CGRP blockade can be expected to help |
| 35268319 | 2022 | Case reports and review | J Clin Med | Anti-CGRP antibodies may have a role in preventing migraine aura, but evidence is scarce |
| 40341526 | 2025 | Review/observational | Headache | Two genetic conditions with prominent migraine responded to CGRP antagonist therapy |
| 40191903 | 2025 | Case report | Rev Neurol | Wearing-off effect managed with eptinezumab in chronic migraine with aura that was refractory to two subcutaneous anti-CGRP antibodies |
| 30725283 | 2019 | Review | Handb Exp Pharmacol | Overview of the role of CGRP in migraine pathophysiology |
| 32699706 | 2020 | Review | Cureus | Review of CGRP antagonists in episodic and chronic migraine |
One further paper, PMID 33550872 (Pain Management, 2021), is a rimegepant review that only lists eptinezumab among new preventive options, so it was left out of the table as off-target.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA761119 | Vyepti (Lundbeck Pharmaceuticals LLC) | Injection (intravenous) | Not listed in the source data |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found in the queried data.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence is at L4 and amounts to a research question. There are no registered trials, and no publication studies brainstem aura directly. The literature also suggests aura may involve CGRP-independent pathways such as PACAP. The high TxGNN score likely reflects the parent migraine indication.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are missing and block safety screening
- Mechanism of action data from DrugBank
- Direct clinical evidence in brainstem aura, such as a subgroup analysis or a small prospective study
- Clarification of how brainstem aura differs mechanistically from the migraine-with-aura populations already studied
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.